HomeCompareINPX vs PFE

INPX vs PFE: Dividend Comparison 2026

INPX yields 3795.07% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INPX wins by $4322908420209.56M in total portfolio value
10 years
INPX
INPX
● Live price
3795.07%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4322908420209.61M
Annual income
$4,109,875,340,592,546,300.00
Full INPX calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — INPX vs PFE

📍 INPX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINPXPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INPX + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INPX pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INPX
Annual income on $10K today (after 15% tax)
$322,580.65/yr
After 10yr DRIP, annual income (after tax)
$3,493,394,039,503,664,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, INPX beats the other by $3,493,394,039,503,641,600.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INPX + PFE for your $10,000?

INPX: 50%PFE: 50%
100% PFE50/50100% INPX
Portfolio after 10yr
$2161454210104.83M
Annual income
$2,054,937,670,296,286,200.00/yr
Blended yield
95.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

INPX
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
0.0
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INPX buys
0
PFE buys
0
No recent congressional trades found for INPX or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINPXPFE
Forward yield3795.07%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$4322908420209.61M$49.6K
Annual income after 10y$4,109,875,340,592,546,300.00$26,258.71
Total dividends collected$4308344536195.87M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: INPX vs PFE ($10,000, DRIP)

YearINPX PortfolioINPX Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$390,207$379,506.64$9,153$693.39+$381.1KINPX
2$14,257,335$13,839,814.20$8,593$849.25+$14.25MINPX
3$487,851,509$472,596,159.98$8,336$1,066.78+$487.84MINPX
4$15,635,175,719$15,113,174,604.74$8,437$1,384.80+$15635.17MINPX
5$469,405,186,241$452,675,548,221.17$9,013$1,875.40+$469405.18MINPX
6$13,203,569,445,578$12,701,305,896,300.34$10,306$2,680.72+$13203569.44MINPX
7$348,021,399,066,998$333,893,579,760,230.00$12,820$4,101.38+$348021399.05MINPX
8$8,597,439,308,359,841$8,225,056,411,358,154.00$17,673$6,826.70+$8597439308.34MINPX
9$199,096,336,090,714,370$189,897,076,030,769,340.00$27,543$12,591.86+$199096336090.69MINPX
10$4,322,908,420,209,610,000$4,109,875,340,592,546,300.00$49,560$26,258.71+$4322908420209.56MINPX

INPX vs PFE: Complete Analysis 2026

INPXStock

Inpixon, together with its subsidiaries, provides solutions and technologies worldwide. The company operated through three segments: Indoor Intelligence, Saves, and Shoom. The Indoor Intelligence segment offers smart office app provide a frictionless work environment; executive briefing centers, an omni-channel software platform provides a virtual briefing platform allowing organizations to offer a personalized experience for in-office, remote, and hybrid meetings; events, offers a mobile first and virtual event platform to connect remote and in person audiences in a fully branded, end to end event experience; inpixon mapping solution which provides users with the tools to add intelligence to complex indoor spaces; augmented reality and 3D allow businesses to scan a space and attach AR content persistently to any position; analytics and insights, a cloud-based analytics platform allows data from multiple sensors and data sources to be visualized for action by the operator; and on-device positioning solution enables a smartphone's precise location to be displayed to a user in a mobile app. This segment also provides Internet of Things (IoT) software-as-a-service platform, IoT devices, sensors and tags, video integration, security, and transceiver/modules. The Shoom segment offers digital solutions or cloud-based applications and analytics for the media and publishing industry, including eTearsheets and eInvoice. The SAVES provides a set of data analytics and statistical visualization software solutions for engineers and scientists, as well as data analytics and statistical visualization tools which comprise SigmaPlot, SigmaStat, SYSTAT, PeakFit, TableCurve 2D, TableCurve 3D, SigmaScan and MYSTAT. The company was formerly known as Sysorex Global and changed its name to Inpixon in March 2017. Inpixon is headquartered in Palo Alto, California.

Full INPX Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this INPX vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INPX vs SCHDINPX vs JEPIINPX vs OINPX vs KOINPX vs MAININPX vs JNJINPX vs MRKINPX vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.